Our Management, Executive Advisors and Scientific Key Opinion Leaders have over a century of experience in life sciences, drug development and emerging Biotechnology and MedTech companies. We are dedicated to building a cardiovascular focused company that can develop products that will improve the lives of millions of people across the globe.
Samuel Dudley Jr., MD, PhD, is a cardiologist who specializes in abnormal heart beats, diastolic heart failure and experimental blood tests and treatments for abnormal heart beats. He sees patients at M Health Fairview Clinics and Surgery Center - Minneapolis and the M Health Fairview University of Minnesota Medical Center - East Bank Hospital. His research interests include cardiac cell replacement therapy, diastolic heart failure and sudden cardiac death. Dr. Dudley is also a professor in the Cardiovascular Division of the Department of Medicine at the University of Minnesota Medical School.
Leadership - CEO with Experience Executing on Strategy and Venture Investment
Serves as CEO, Board Member and advisor to several emerging growth biotechnology companies
Extensive experience with early-stage drug and technology development through role at Lincoln Park Capital LLC, a fundamental equity investor in Life Sciences
Strong operational experience having managed a division of Advocate Health Care and C-suite roles with various emerging health science enterprises
Widespread exposure to capital markets and venture capital
Served as an advisory/licensing consultant ranging from entrepreneurial biotechnology startups to large pharmaceutical companies both in the US and in the Global Market
Graduated from the Feinberg School of Medicine and Internal Medicine Residency at Northwestern University, preceded by The Wharton School of Business and College of Arts & Sciences, University of Pennsylvania
LinkedIn Address: https://www.linkedin.com/in/michael-beaubaire-06966b3/
Overview
A forward-thinking, global strategic leader with diverse management experience, Tom has successfully lead an international organization across multiple disciplines, including corporate leadership, operations (manufacturing/supply chain), business development (M&A, licensing), portfolio management, project management, P&L, sales and marketing. Prior to Hennepin Life Sciences, Tom worked for over 30 years at Upsher-Smith Laboratories in various capacities having progressing levels of responsibility.
Noteworthy
Overview
Dr. Robbins is a bio-pharmaceutical drug development professional and pharmaceutical attorney with over 30 years of broad-based drug development and commercialization experience. As a senior manager, most time has been spent overseeing all areas of research and development, clinical development, regulatory affairs, and legal affairs. As General Counsel he is responsible for all business development and litigation activities including patent and antitrust matters. He is an expert in pharmaceutical/biotech patent and antitrust litigation matters.
Noteworthy
WakeMed Heart & Vascular
Assistant Professor of Medicine
Member Duke Clinical Research Institute
Dr. Kishan Parikh, MD is a cardiology specialist with over 14 years experience. Kishan graduated from Northwestern University Feinberg School Of Medicine in 2009 and completed a residency at University Of Chicago Hospitals Pritzker School Of Medicine.
Neil J. Stone Endowed Professor of Medicine (Cardiology), and Director of the Heart Failure with Preserved Ejection Fraction Program at Northwestern University Feinberg School of Medicine
Stone Professor of Medicine, Director of Research, Bluhm Cardiovascular Institute
Director, Northwestern HFpEF Program
Division of Cardiology, Department of Medicine
Northwestern University, Feinberg School of Medicine, Chicago, IL
Director, Institute for Artificial Intelligence in Medicine, Northwestern University
Endowed Chair, Charles Ezra Daniel for Cardiology
Dr. Zile is the Charles Ezra Daniel Professor of Medicine and Distinguished University Professor at the Medical University of South Carolina; is a member of the Cardiology Division at the Ralph H. Johnson Dept. of Veteran Affairs Health Care System; and is an Adjunct Professor of Bioengineering at Clemson University.
Mike is a preeminent, award-winning researcher focused on basic, translational and clinical research examining the mechanisms underlying the development and progression of heart failure particularly HFpEF. His research has been funded for over 40 years by the NHLBI, VA, DOD, AHA, and industry and been summarized in more than 450 peer-reviewed publications.
Executive Board Chair, Akava Therapeutic and Bolden Therapeutics
Former President & CEO of William Harris Investors
Dr. Polsky is a seasoned biotechnology entrepreneur with two decades of experience both as an investor and operator in the life sciences. He is driven by a desire to improve care for patients and their families.
Charlie received his MD and residency training at the University of Chicago, and undergraduate degree at Yale University. Charlie was CEO of William Harris Investors, has served in numerous board/advisory positions for biotechnology start-up, including Tivorsan, Panacos Therapeutics, 3PrimeDx, SonoGene, Rigimmune, Bolden Therapeutics, ReAx and Akava Therapeutics.
EVP of Operations, AirAnswers
Board Member, Recogen and SmartHealth Catalyzer
Former Head of Venture Investments, Abbot Biotech Ventures and Lead, Cardio-Renal Division
Dr. Kuemmerle is Executive VP of Operations for AirAnswers, Inc., a company devoted to diagnosing indoor air quality. Steve received his Ph.D. in Biochemistry from Northwestern University. He serves as an advisor and board member on various healthcare start-ups.
Steve has over three decades of healthcare industry experience. He was Head of Venture Investments, Abbott Biotech Ventures, Inc., leading the evaluation and execution of equity investments in emerging pharma companies. Prior to that role, Steve served as a director in Abbott’s Global Pharma Licensing Group.
CEO of Molecules to Medicine Advisory Group
President of R&D, Axcella Therapeutics
VP of Business Development, CV and Heart Failure, Johnson & Johnson
Dr. Schecter is the Chief Executive Officer of Molecules to Medicine Advisory Group (MTM AG), a consultancy firm providing state-of-the-art guidance to life sciences companies on translating critical steps in drug development and corporate strategy in multiple therapeutic areas.
She was President of R&D at Axcella, served as CMO, Selecta Biosciences, and has held senior roles at Novartis, J&J, Baxalta and Sanofi.
Alison trained at John Hopkins University School of Medicine, completed her Cardiovascular Fellowship at Harvard Medical School and Cardiology Research Fellowship at Mount Sinai.
Founder, President & CEO, Canary Medical
President & CEO, Correvio Pharma Corp.
Founder, President & CEO, Angiotech Pharmaceuticals
Dr. Bill Hunter is President and CEO of Canary Medical Inc, a company developing proprietary implantable sensor to provide real time analytical data. He was Founder/CEO of Angiotech (ANPI), one of the first drug eluting stent makers and CEO of Correvio (CORV) a specialty pharma company with an A fib product for acute cardioversion.
Bill has a Doctorate of Medicine, Master of Science from the University of British Columbia and a BS from McGill University. With over 200 patents and patent applications, including the discovery and development of Persona IQ and the TAXUS® Drug Eluting Coronary Stent, Bill has overseen the development of products used in over 50 million patients, generating revenues of over $25 billion.
Diastol Therapeutics
4925 Weston Lane N
Plymouth, MN 55446
Phone: 312-238-9017
michaelb@diastol.com
© 2024 Diastol Therapeutics